Biomedical Occupation or Discipline
UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure
UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853
Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results
Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases
Biomarker Data’s Potential to Expedite Approval of Edgewise’s Dystrophy Drug
Biomarkers, drug development, Edgewise Therapeutics, Becker muscular dystrophy, regulatory approval
Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations
Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships
Novo Holdings to Finalize $16.5B Acquisition of Catalent Following Regulatory Clearance
Novo Holdings, Catalent, Acquisition, Regulatory Clearance, Life Sciences, Pharmaceutical Development
FDA Approves Expanded Use of VTAMA and Nemluvio for Atopic Dermatitis Treatment
FDA approval, atopic dermatitis, VTAMA, Nemluvio, Galderma, Organon, dermatology, skin conditions
Medtronic’s PillCam Genius SB Completes First Patient Procedure for GI Diagnostics
Medtronic, PillCam Genius SB, Capsule Endoscopy, GI Diagnostics, At-Home Ingestion, Telehealth
AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics
AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics
Gilead Sciences Appoints Dietmar Berger as Chief Medical Officer to Spearhead R&D Revamp
Gilead Sciences, Dietmar Berger, Chief Medical Officer, R&D Reset, Biotechnology, Pharmaceutical Industry
Pleno Secures $25M Funding for Commercial Launch, Appoints New CEO from Illumina
Pleno, multiomics, funding, commercial launch, new CEO, Illumina